Kairos Pharma, Ltd.
KAPAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | maintain | Buy | Nov 19, 2025 |
| D. Boral Capital | maintain | Buy | Nov 4, 2025 |
| D. Boral Capital | maintain | Buy | Oct 20, 2025 |
| D. Boral Capital | maintain | Buy | Oct 7, 2025 |
| D. Boral Capital | maintain | Buy | Sep 19, 2025 |
| D. Boral Capital | maintain | Buy | Jul 16, 2025 |
| D. Boral Capital | maintain | Buy | Jun 4, 2025 |
| D. Boral Capital | maintain | Buy | Apr 17, 2025 |
| D. Boral Capital | maintain | Buy | Mar 31, 2025 |
| D. Boral Capital | maintain | Buy | Mar 20, 2025 |
| D. Boral Capital | maintain | Buy | Feb 26, 2025 |
| D. Boral Capital | maintain | Buy | Feb 18, 2025 |
| D. Boral Capital | maintain | Buy | Feb 12, 2025 |
| D. Boral Capital | maintain | Buy | Jan 22, 2025 |
| D. Boral Capital | maintain | Buy | Nov 14, 2024 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.63| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.42 | $-0.63 | — | — |
| May 13, 2026 | $-0.08 | $-0.07 | — | — |
| Apr 21, 2026 | $-0.07 | $-0.84 | — | — |
| Nov 13, 2025 | $-0.49 | $-0.70 | — | — |
| Aug 13, 2025 | $-0.08 | $-0.42 | — | — |
| Apr 15, 2025 | $-0.08 | $-0.05 | — | — |
| Feb 26, 2025 | $-0.42 | $-0.42 | — | — |
| Nov 14, 2024 | $-0.05 | $-0.02 | — | — |
News
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting th…
LOS ANGELES--(BUSINESS WIRE)--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026.
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe. Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc. , is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality.
Kairos Pharma Ltd. (NYSE:KAPA) on Tuesday announced interim efficacy results from its ongoing Phase 2 clinical trial testing ENV-105 alongside apalutamide for patients with metastatic castration-resistant prostate cancer.
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) be…
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference's webs…
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #HCW--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Presentation Date: September 14, 2026 Time: 4:00 PM Eastern Time (Holmes 1) …
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American…